Dupilumab Becomes First Biologic Approved for COPD: Reduces Exacerbations by 30%

Why Is a Biologic for COPD Such a Big Deal?

COPD affects an estimated 380–400 million people worldwide and kills approximately 3.2 million annually according to the World Health Organization, making it the third leading cause of death globally. Despite its enormous burden, treatment options have been limited to inhaled bronchodilators (beta-agonists, anticholinergics) and corticosteroids — broadly acting medications that provide symptom relief but do not address the underlying inflammatory pathology.

Meanwhile, asthma has seen a revolution in biologic therapies over the past decade, with multiple targeted agents approved. COPD was long considered a single disease not amenable to precision medicine. The recognition that approximately 20–30% of COPD patients have a distinct type 2 inflammatory phenotype (characterized by elevated blood eosinophils) has changed this paradigm. Dupilumab's approval validates the concept of targeted therapy in COPD and opens the door for additional biologics in the future.

How Does Dupilumab Work in COPD?

Dupilumab is a fully human monoclonal antibody that inhibits the signaling of both IL-4 and IL-13 by blocking the IL-4 receptor alpha (IL-4Rα) subunit, a shared component of both the IL-4 and IL-13 receptor complexes. These cytokines drive type 2 inflammation — a specific inflammatory pathway characterized by eosinophil activation, mucus hypersecretion, and tissue remodeling.

In COPD patients with elevated blood eosinophils (≥300 cells/μL), type 2 inflammation plays a significant pathogenic role. By blocking this pathway, dupilumab reduces eosinophilic airway inflammation (with marked decreases in blood eosinophil counts observed in trials), decreases mucus production (improving airway clearance), and may slow the progressive airway remodeling that drives disease worsening. The clinical result is fewer exacerbations and improved lung function.

Which COPD Patients Are Eligible for Dupilumab?

The FDA-approved indication specifies dupilumab for adults with inadequately controlled COPD with an eosinophilic phenotype, defined as blood eosinophils ≥300 cells/μL. Patients must be on maximized background inhaled therapy (typically triple therapy: LABA/LAMA/ICS) and continue to experience exacerbations despite this treatment.

Identifying eligible patients requires only a routine complete blood count with differential — eosinophils ≥300 cells/μL are found in an estimated 20–30% of COPD patients. In the BOREAS trial, patients in the highest eosinophil subgroups showed the greatest benefit, while those with lower eosinophils showed less benefit, confirming the importance of biomarker-guided patient selection. This precision medicine approach ensures that dupilumab is directed at the patients most likely to respond.

What Are the Side Effects and Cost of Dupilumab for COPD?

Dupilumab was well tolerated in the COPD trials, with an overall safety profile consistent with its established use in atopic dermatitis and asthma. Injection site reactions were the most common adverse event (more frequent with dupilumab than placebo), typically mild and transient. Other notable side effects included back pain, joint pain, and a slightly higher incidence of herpes zoster compared to placebo.

Overall serious adverse event rates were comparable or lower in the dupilumab group compared to placebo, driven largely by fewer severe COPD exacerbations in the treatment group. No major new safety signals emerged in the COPD population. The estimated annual cost is approximately $36,000 or more, broadly comparable to biologic pricing for asthma and other inflammatory conditions. Sanofi offers copay assistance programs for eligible patients.